港股異動 | 亞盛醫藥-B(6855.HK)大漲逾13% 四項臨牀進展將於2021ASCO年會發布
格隆匯4月21日丨亞盛醫藥-B(6855.HK)直線拉昇大漲13.3%,報36.2港元創近2個月新高,成交額超1億港元,總市值91億港元。亞盛醫藥今日宣佈,公司三個細胞凋亡管線品種的四項臨牀研究入選2021年美國臨牀腫瘤學會(ASCO)年會,其中兩項進展獲選口頭報吿,分別為Bcl-2抑制劑APG-2575的全球I期臨牀研究、新型MDM2-p53抑制劑APG-115聯合帕博利珠單抗的全球II期臨牀研究。根據亞盛醫藥在2020年12月披露的數據,APG-2575針對R/R CLL的初步臨牀研究結果顯示,在可評估患者中的總緩解率(ORR)達到70%,且耐受性和安全性良好。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.